Skip to main content

Table 2 Baseline respiratory mechanics and clinical outcomes

From: Effect of prone positioning on oxygenation and static respiratory system compliance in COVID-19 ARDS vs. non-COVID ARDS

Variables

COVID-19 ARDS

Non-COVID ARDS

Entire group N = 23

Entire group N = 145

P valuea

PaO2/FiO2-matched N = 23

P valuea

Compliance-matched N = 23

P valuea

Arterial blood gas analysis

 pH

7.37 (7.34–7.39)

7.34 (7.28–7.40)

0.173

7.36 (7.26–7.40)

0.291

7.34 (7.28–7.41)

0.568

 PaCO2, mmHg

44 (40–49)

49 (40–55)

0.139

48 (45–54)

0.071

46 (37–54)

0.860

 PaO2, mmHg

75 (66–80)

71 (62–85)

0.467

79 (65–93)

0.391

69 (55–78)

0.097

 HCO3, mEq/L

24.9 (24.1–28.4)

24.2 (21.5–27.3)

0.161

23.3 (21–28.6)

0.191

23.3 (18.6–28.6)

0.240

Ventilator FiO2

0.7 (0.6–0.8)

0.8 (0.65–1.0)

0.047

0.75 (0.6–0.9)

0.537

0.75 (0.7–1.0)

0.221

PaO2/FiO2 ratio, mmHg

107 (92–132)

96 (74–120)

0.037

107 (92–131)

1.000

90 (72–104)

0.007

PEEP, cmH2O

12 (9–13)

10 (8–11)

0.016

10 (7–10)

0.063

10 (8–11)

0.135

Driving pressure, cmH2O

13 (12–16)

18 (15–21)

< 0.001

18 (15–22)

0.001

15 (13–18)

0.096

Respiratory rate, breaths/min

21 (19–27)

27 (24–30)

0.002

26 (25–30)

0.012

24 (21–30)

0.116

Tidal volume per PBW, mL/kg

6.3 (5.6–7.0)

6.6 (6.0–7.3)

0.126

6.4 (5.9–7.2)

0.734

6.5 (5.9–9.0)

0.177

Minute ventilation per PBW, mL/kg/min

140 (123–171)

177 (145–200)

< 0.001

167 (133–193)

0.044

173 (141–194)

0.003

Static respiratory system compliance, mL/cmH2O

27.2 (21.9–32.7)

21.9 (18.2–26.5)

0.005

20.0 (15.6–27.2)

0.008

27.2 (21.9–32.7)

0.983

Ventilatory ratio

1.7 (1.4–2.0)

2.2 (1.7–2.7)

 < 0.001

2.1 (1.7–2.5)

0.015

2.2 (1.7–2.6)

0.002

Laboratory results

 White blood cell, 103/μL

10.46 (6.53–16.04)

13.36 (5.73–17.77)

0.717

15.73 (13.14–23.71)

0.008

10.01 (5.73–16.86)

0.904

 Segmented neutrophil, 103/μL

9.66 (5.88–14.57)

11.42 (4.93–15.06)

0.906

14.40 (11.53–19.56)

0.014

9.56 (4.53–14.43)

0.684

 Lymphocyte, 103/μL

0.69 (0.48–0.86)

0.43 (0.18–0.84)

0.047

0.70 (0.27–0.98)

0.895

0.51 (0.16–0.88)

0.249

 C-reactive protein, mg/dL

10.9 (6.3–19.8)

13.5 (6.6–21.5)

0.234

13.8 (7.6–21.5)

0.449

19.2 (9.1–25.7)

0.037

 RT-PCR for SARS-CoV-2

  Ct value for env gene

23.01 ± 4.99

      

  Ct value for RdRp gene

22.60 ± 5.22

      

Adjunctive therapies

 Inhaled nitric oxide

8 (34.8%)

56 (38.6%)

0.725

4 (17.4%)

0.179

8 (34.8%)

1.000

 Renal replacement therapy

4 (17.4%)

29 (20.0%)

1.000

2 (8.7%)

0.665

7 (30.4%)

0.491

 ECMO or ECCO2R

3 (13.0%)

7 (4.8%)

0.141

0 (0.0%)

0.233

2 (8.7%)

1.000

 Tracheostomy

12 (52.2%)

59 (40.7%)

0.300

15 (65.2%)

0.369

6 (26.1%)

0.070

90-days clinical outcome

 Successful discontinuation of mechanical ventilation

16 (69.6%)

27 (18.6%)

< 0.001

5 (21.7%)

0.005

4 (17.4%)

0.001

 Dependent on mechanical ventilation

2 (8.7%)

11 (7.6%)

 

5 (21.7%)

 

1 (4.3%)

 

 Death

5 (21.7%)

107 (73.8%)

 

13 (56.6%)

 

18 (78.3%)

 

 Ventilator free days

45 (0–82)

0 (0–0)

< 0.001

0 (0–0)

0.002

0 (0–0)

0.002

  1. ARDS acute respiratory distress syndrome, Ct value cycle threshold value, ECCO2R extracorporeal carbon dioxide removal, ECMO extracorporeal membrane oxygenation, FiO2 fraction of inspired oxygen, PaCO2 partial pressure of carbon dioxide, PaO2 partial pressure of oxygen, PBW predicted body weight, PEEP positive end expiratory pressure, RT-PCR reverse transcription polymerase chain reaction
  2. aP values are for comparison between patients with COVID-19 ARDS and patients with non-COVID ARDS
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us